Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen

Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma

Curr Res Transl Med.

Ghobadi A

doi: 10.1016/

T Cells

Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies

Lancet

Benjamin R, Graham C, Yallop D, Jozwik A, Mirci-Danicar OC, Lucchini G, Pinner D, Jain N, Kantarjian H, Boissel N, Maus MV, Frigault MJ, Baruchel A, Mohty M, Gianella-Borradori A, Binlich F, Balandraud S, Vitry F, Thomas E, Philippe A, Fouliard S, Dupouy S, Marchiq I, Almena-Carrasco M, Ferry N, Arnould S, Konto C, Veys P, Qasim W, UCART19 Group.

doi: 10.1016/S0140-6736(20)32334-5

T Cells

Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection?

Lancet Haematol

Gudiol C, Lewis RE, Strati P, Kontoyiannis DP

doi: 10.1016/S2352-3026(20)30376-8

T CellsImmune Response

Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline

J Clin Oncol

Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Funchain P, Jaiyesimi I, Mammen JS, Naidoo J, Naing A, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Bollin K, Ghosh M

doi: 10.1200/JCO.21.01992

Immunotherapy

CAR T Cells Beyond Cancer: Hope for Immunomodulatory Therapy of Infectious Diseases

Front Immunol.

Seif M, Einsele H, Löffler J

doi: 10.3389/fimmu.2019.02711.

Immunodeficiency

Serum B cell maturation antigen (BCMA) levels differentiate primary antibody deficiencies

J Allergy Clin Immunol Pract.

Maglione PJ, Ko HM, Tokuyama M, Gyimesi G, Soof C, Li M, Sanchez E, Chen H, Radigan L, Berenson J, Cunningham-Rundles C

doi: 10.1016/j.jaip.2019.08.012.

Immunotherapy

Itacitinib (INCB039110), a JAK1 inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-Cell Therapy

Clin Cancer Res

Huarte E, O'Conner RS, Peel MT, Nunez-Cruz S, Leferovich J, Juvekar A, Yang YO, Truong L, Huang T, Naim A, Milone MC, Smith PA

doi: 10.1158/1078-0432.CCR-20-1739

Vitiligo

Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells

Neurology.

Ruck T, Pfeuffer S, Schulte-Mecklenbeck A, Gross CC, Lindner M, Metze D, Ehrchen J, Sondermann W, Pul R, Kleinschnitz C, Wiendl H, Meuth SG, Klotz L

doi: 10.1212/WNL.

T Cells

Counter-regulation of regulatory T cells by autoreactive CD8+ T cells in rheumatoid arthritis

doi: 10.1016/j.jaut.2019.02.001.

Related content

Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma

Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies

Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection?

Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline

CAR T Cells Beyond Cancer: Hope for Immunomodulatory Therapy of Infectious Diseases

Serum B cell maturation antigen (BCMA) levels differentiate primary antibody deficiencies

Itacitinib (INCB039110), a JAK1 inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-Cell Therapy

Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells

Counter-regulation of regulatory T cells by autoreactive CD8+ T cells in rheumatoid arthritis